MESOBLAST LTDMESOEarnings & Financial Report
Nasdaq
Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004.
NextFeb 27, 2026
MESO Q3 2023 Key Financial Metrics
Revenue
$1.9M
Gross Profit
N/A
Operating Profit
N/A
Net Profit
$-18.6M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
-959.3%
YoY Growth
-3.6%
EPS
$-0.03
Financial Flow
MESOBLAST LTD Q3 2023 Financial Summary
MESOBLAST LTD reported revenue of $1.9M for Q3 2023, with a net profit of $-18.6M (-959.3% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $1.9M |
|---|---|
| Net Profit | $-18.6M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2023 |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|
| Revenue | $3.6M | $2.4M | $2.0M | $1.5M | $2.1M | $1.9M |
| YoY Growth | 175.4% | 6.3% | 5.0% | -58.2% | -10.4% | -3.6% |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|
| Assets | $721.8M | $704.4M | $681.7M | $684.5M | $668.1M | $650.4M |
| Liabilities | $162.1M | $168.9M | $164.6M | $161.7M | $168.1M | $168.3M |
| Equity | $559.7M | $535.5M | $517.1M | $522.8M | $500.0M | $482.2M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|
| Operating CF | $-19.6M | $-16.8M | $-15.5M | $-14.3M | $-16.5M | $-16.3M |